Z6尊龙
Other Affiliated Sites
Techdow Pharma China
Techdow Pharma UK
Techdow Pharma Poland
Techdow Pharma Italy
Techdow Pharma Spain
Techdow Pharma Germany
Techdow Pharma US
Cytovance Biologics
SPL
Simplified Chinese
Traditional Chinese
About Hepalink
Group Profile
Corporate Philosophy
Milestones
Leadership Team
Scientific Advisory Board
Our Businesses
Heparin Business
Global Industrial Chain
Global Heparin Injections Business
Product Profile
CDMO Services
Innovative Drugs
Global Manufacturing
Company News
Investor Relations
Corporate Governance
Disclosures
Stock Information
IR Events
IR Contact
Join Us
Career Development
Job Opportunities
Campus Recruitment
Contact Us
Create Value for Investors Through
Safe and Stable Operations
Corporate Governance
Disclosures
Stock Information
IR Events
IR Contact
Disclosures
A-Share Information
H-Share Information
Financial Reports
Announcements
2017.12.12
关于控股子公司获得美国FDA准许开展II期临床试验的通告
2017.12.05
关于公司使用自有资金对Resverlogix Corp.举行投资的希望通告
2017.11.11
关于收到《中国证监会行政允许项目审查一次反响意见通知书》的通告
2017.11.11
中国证监会行政允许项目审查一次反响意见通知书
2017.11.07
“16Z6尊龙”2017年付息通告
2017.10.26
关于全资孙公司通过美国FDA现场检查的通告
2017.10.21
关于控股子公司临床试验希望的通告
2017.10.19
关于收到《中国证监会行政允许申请受理通知书》的通告
2017.10.14
第四届董事会第七次聚会决议通告
2017.10.14
关于使用自有资金对Resverlogix Corp.举行投资的通告
第一页
上一页
66
67
68
69
70
下一页
最后一页
About Hepalink
Group Profile
Corporate Philosophy
Milestones
Leadership Team
Scientific Advisory Board
Our Businesses
Heparin Business
CDMO Services
Innovative Drugs
Global Manufacturing
Company News
Investor Relations
Corporate Governance
Disclosures
Stock Information
IR Events
IR Contact
Join Us
Career Development
Job Opportunities
Campus Recruitment
Contact Us
Official WeChat Account
Legal Statement
·
Environmental Disclosure
Copyright ? 2024 Hepalink Group. All Rights Reserved.
【网站地图】
【sitemap】